Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental ancrod (Arvin) for acute ischemic stroke: nursing implications.

H Jahnke1

  • 1Barrow Neurological Institute, Phoenix, Arizona.

The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses
|December 1, 1991
PubMed
Summary

Early intervention with ancrod, a defibrinogenating agent, can reverse impending stroke. Prompt treatment within 6 hours is crucial for improving neurological outcomes in acute ischemic stroke patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in the fatty acid composition of KB-cells and gingival keratinocytes is culture medium additive dependent.

Biomedical chromatography : BMC·2006
Same author

Bacterial colonization on different suture materials--a potential risk for intraoral dentoalveolar surgery.

Journal of biomedical materials research. Part B, Applied biomaterials·2005
Same author

Organic dyestuffs as catalysts for fuel cells.

Topics in current chemistry·1976
Same author

Steroids and related products. X. 17 alpha-Bromoprogesterone, a new potent gestogen.

Canadian journal of biochemistry and physiology·1957

Area of Science:

  • Neurology
  • Vascular Medicine
  • Pharmacology

Background:

  • Timely restoration of cerebral blood flow is critical for reversing ischemic brain damage and improving stroke patient outcomes.
  • Ancrod, derived from Malayan pit viper venom, effectively reduces fibrinogen levels, promoting defibrinogenation.
  • Current research focuses on ancrod's efficacy in acute nonhemorrhagic ischemic stroke, requiring treatment initiation within 6 hours of symptom onset.

Purpose of the Study:

  • To evaluate the effectiveness of ancrod in treating acute or progressing nonhemorrhagic ischemic stroke.
  • To determine the optimal time window for ancrod administration in stroke patients, emphasizing early intervention.

Main Methods:

  • A clinical trial involving patients with acute or progressing nonhemorrhagic ischemic stroke.

Related Experiment Videos

  • Administration of ancrod, a defibrinogenating agent, within 6 hours of stroke onset.
  • Monitoring patients for potential bleeding complications, with nurses playing a key assessment role.

    • Main Results:

    • Ancrod demonstrated rapid and effective defibrinogenation in human subjects.
    • The study highlights the critical 6-hour treatment window for ancrod in ischemic stroke.

    Conclusions:

    • Early and aggressive intervention with ancrod shows promise in reversing impending cerebral infarction.
    • Community education on stroke warning signs is vital for timely patient presentation and improved neurological outcomes.